Citation Report
List of articles citing

Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR

DOI: 10.1016/0304-3940(87)90696-3
Neuroscience Letters, 1987, 79, 195-200.

Source: https://exaly.com/paper-pdf/19180232/citation-report.pdf
Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
733	Major histocompatibility complex antigen expression on rat microglia following epidural kainic acid lesions. **1988**, 20, 147-57		152
732	Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. **1988**, 76, 550-7		322
731	Histological signs of immune reactions against allogeneic solid fetal neural grafts in the mouse cerebellum depend on the MHC locus. **1988**, 73, 15-22		54
730	Antibodies to cholinergic neurons in Alzheimer's disease. **1988**, 51, 479-85		49
729	Occurrence of HLA-DR reactive microglia in Alzheimer's disease. **1988**, 540, 319-23		40
728	Characterisation of microglia isolated from adult human and rat brain. **1988**, 19, 177-89		115
727	Immune system associated antigens expressed by cells of the human central nervous system. *Neuroscience Letters*, **1988**, 94, 17-22	3.3	118
726	Immunologic and tissue culture approaches to the neurobiology of aging. **1988**, 9, 759-62		13
725	Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. *Neuroscience Letters*, **1988**, 91, 259-64	3.3	208
724	Antibodies in serum of patients with Alzheimer's disease cause immunolysis of cholinergic nerve terminals from the rat cerebral cortex. **1989**, 16, 528-34		10
723	Immunization of rats with cholinergic neurons induces behavioral deficits. **1989**, 1, 63-76		9
722	Examination of brains of AIDS cases for human immunodeficiency virus and human cytomegalovirus nucleic acids. **1989**, 52, 583-90		17
721	Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease. **1989**, 80, 554-60		32
720	A case of adult-onset dementia with argyrophilic grains. **1989**, 26, 685-9		46
719	Loss of glutaminase-positive cortical neurons in Alzheimer's disease. **1989**, 14, 353-8		32
718	Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. **1989**, 77, 569-75		249
717	Activation of the classical complement pathway in brain tissue of Alzheimer patients. *Neuroscience Letters*, **1989**, 107, 341-6	3.3	334

716	Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. *Neuroscience Letters*, **1989**, 101, 288-92	3.3	157
715	Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. **1989**, 24, 173-82		748
714	Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. **1989**, 489, 247-53		155
713	Beta-amyloid deposition and paired helical filament formation: which histopathological feature is more significant in Alzheimer's disease?. **1989**, 10, 402-4; discussion 412-4		18
712	Immune system response in Alzheimer's disease. **1989**, 16, 516-27		408
711	Cortical glutaminase, beta-glucuronidase and glucose utilization in Alzheimer's disease. **1989**, 16, 511-5		32
710	MHC antigen expression in spontaneous and induced rejection of neural xenografts. **1990**, 82, 129-40		17
709	Human herpes virus infections and Alzheimer's disease. **1990**, 16, 213-23		52
708	Immunization with cholinergic cell bodies induces histopathological changes in rat brains. **1990**, 13, 71-80		4
707	Microglia in cerebellar plaques in Alzheimer's disease. **1990**, 80, 493-8		82
706	Targeting of adoptively transferred experimental allergic encephalitis lesion at the sites of wallerian degeneration. **1990**, 80, 521-6		55
705	Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease. **1990**, 79, 537-44		28
704	An animal model of prophylactic cranial irradiation: histologic effects at acute, early and delayed stages. **1990**, 18, 1051-60		63
703	Anti-inflammatory drugs and Alzheimer disease. **1990**, 335, 1037		353
702	Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. *Neuroscience Letters*, **1990**, 112, 161-6	3.3	61
701	Immunostaining of human brain capillaries by antibodies to very late antigens. **1990**, 26, 213-8		39
700	The blood-brain barrier protects foreign antigens in the brain from immune attack. **1990**, 108, 114-21		75
699	Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. **1990**, 110, 93-104		138

698	Patterns of immune rejection of mouse neocortex transplanted into neonatal rat brain, and effects of host immunosuppression. **1990**, 519, 133-43		36
697	Activation and proliferation of the isolated microglia by colony stimulating factor-1 and possible involvement of protein kinase C. **1990**, 509, 119-24		185
696	Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. **1990**, 523, 273-80		150
695	Anti-neuronal antibodies similar to those found in Alzheimer's disease induce memory dysfunction in rats. **1991**, 40, 297-305		38
694	A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease. *Neuroscience Letters*, **1991**, 121, 271-3	3.3	13
693	Antibodies in the cerebrospinal fluid of some Alzheimer's disease patients recognize amoeboid microglial cells in the developing rat central nervous system. **1991**, 41, 739-52		39
692	Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. **1991**, 544, 315-9		98
691	Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. **1991**, 32, 19-28		108
690	Antibody in the CSF of patients with multiple system atrophy reacts specifically with rat locus ceruleus. **1991**, 106, 96-104		15
689	Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimer's disease. **1991**, 12, 13-8		73
688	Reactive Astrocytes Express Acidic Fibroblast Growth Factor in Alzheimer's Disease Brain. **1991**, 2, 64-70		
687	Alzheimer's disease and cellular aging: membrane-related events as clues to primary mechanisms. **1991**, 37, 95-112		51
686	Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. **1991**, 60, 329-36		66
685	Extracellular neurofibrillary tangles associated with degenerating neurites and neuropil threads in Alzheimer-type dementia. **1991**, 81, 603-9		39
684	Increased senile plaques without microglia in Alzheimer's disease. **1991**, 81, 242-7		60
683	Phagocytosis of beta/A4 amyloid fibrils of the neuritic neocortical plaques. **1991**, 81, 588-90		83
682	Differential appearance of autoantibodies to human brain S100 protein, neuron specific enolase and myelin basic protein in psychiatric patients. **1991**, 60, 119-27		29
681	Immune responses in brains of Alzheimer's and Parkinson's disease patients: hypothesis and reality. **1992**, 3, 79-98		18

680	Some immunohistochemical features of argyrophilic grain dementia with normal cortical choline acetyltransferase levels but extensive subcortical pathology and markedly reduced dopamine. **1992**, 5, 3-13		18
679	The role of macrophages in models of neurological and psychiatric disorder. **1992**, 22, 551-5		9
678	Brain macrophages: evaluation of microglia and their functions. **1992**, 17, 61-74		395
677	Complements, microglial cells and amyloid fibril formation. **1992**, 143, 614-6		22
676	Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. **1992**, 14, 109-16		125
675	Cerebrospinal fluid antibodies: an indicator for immune responses in Alzheimer's disease. **1992**, 143, 663-7		7
674	Activated microglia and cerebral amyloid deposits in Alzheimer's disease. **1992**, 143, 646-9		31
673	Immunoblot detection of antibodies to myelin basic protein in Alzheimer's disease patients. *Neuroscience Letters*, **1992**, 147, 25-8	3.3	14
672	Acute phase proteins but not activated microglial cells are present in parenchymal beta/A4 deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. *Neuroscience Letters*, **1992**, 140, 137-40	3.3	24
671	MAO A and B Immunoreactivity in the Hippocampus, Temporal Cortex and Cerebellum of Normal Controls and of Patients with Senile Dementia of the Alzheimer Type (Part 2 of 2). **1992**, 3, 277-281		
670	Amyotrophic Lateral Sclerosis, Parkinson Disease and Alzheimer Disease: Phylogenetic Disorders of the Human Neocortex Sharing Many Characteristics. **1992**, 19, 117-123		62
669	Evidence that neurofibrillary tangles undergo glial modification. **1992**, 85, 101-4		19
668	Long-term survival of mouse corpus callosum grafts in neonatal rat recipients, and the effect of host sensitization. **1992**, 31, 33-45		17
667	Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy. **1992**, 31, 428-42		86
666	Reactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage. **1992**, 31, 443-53		78
665	MHC class II-positive microglia in human brain: association with Alzheimer lesions. **1992**, 33, 549-58		167
664	Microglia in degenerative neurological disease. **1993**, 7, 84-92		523
663	Reactive glia as rivals in regulating neuronal survival. **1993**, 7, 102-10		278

662	Early and rapid de novo synthesis of Alzheimer beta A4-amyloid precursor protein (APP) in activated microglia. **1993**, 9, 199-210	104
661	Optic nerve degeneration induces the expression of MHC antigens in the rat visual system. **1993**, 336, 613-27	35
660	Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. **1993**, 35, 297-304	78
659	Interleukin-2 as a neurotrophic factor for supporting the survival of neurons cultured from various regions of fetal rat brain. **1993**, 35, 305-11	73
658	Columnar arrangement of beta-amyloid protein deposits in the cerebral cortex of patients with Alzheimer's disease. **1993**, 85, 400-3	9
657	The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals. **1993**, 19, 261-8	29
656	Neuronophagia in the motor cortex in amyotrophic lateral sclerosis. **1993**, 19, 390-7	36
655	Immunohistochemical study of alpha 2 macroglobulin receptor in Alzheimer and control postmortem human brain. **1993**, 18, 153-60	70
654	beta-Amyloid peptides induce degeneration of cultured rat microglia. **1993**, 624, 121-5	76
653	Carbachol increases intracellular free calcium in cultured rat microglia. **1993**, 621, 59-64	57
652	Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease. **1993**, 57, 225-34	15
651	Microglia-derived plasminogen enhances neurite outgrowth from explant cultures of rat brain. **1993**, 11, 227-37	50
650	Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. **1993**, 18, 329-34	43
649	The immunopathology of Alzheimer's disease and some related disorders. **1993**, 3, 333-47	66
648	Human retinal microglia express phenotypic characteristics in common with dendritic antigen-presenting cells. **1993**, 45, 183-91	66
647	Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. **1993**, 48, 189-98	114
646	Brain glia release factors with opposing actions upon neuronal survival. **1993**, 13, 29-37	398
645	Immunohistochemical and in situ hybridisation detection of adenovirus early region 1A (E1A) gene in the microglia of human brain tissue. **1994**, 47, 275-7	5

644	Transforming growth factor-beta protects human neurons against beta-amyloid-induced injury. **1994**, 23, 159-78		69
643	Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. **1994**, 38, 214-20		88
642	Brain macrophages stimulate neurite growth and regeneration by secreting thrombospondin. **1994**, 38, 221-33		126
641	Alzheimer's disease cerebrospinal fluid antibodies display selectivity for microglia. Investigations with cell cultures and human cortical biopsies. *Molecular Neurobiology*, **1994**, 9, 41-54	6.2	21
640	MHC class II expression by microglia in tetanus toxin-induced experimental epilepsy in the rat. **1994** , 20, 392-8		27
639	Expression of MRP14, 27E10, interferon-alpha and leukocyte common antigen by reactive microglia in postmortem human brain tissue. **1994**, 50, 195-201		96
638	Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. **1994**, 53, 83-90		63
637	The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. **1994**, 650, 20-31		109
636	Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. **1994**, 645, 78-84		95
635	Upregulation and induction of major histocompatibility complex class I and II antigens on microglial cells in early postnatal rat brain following intraperitoneal injections of recombinant interferon-gamma. **1994**, 60, 959-67		35
634	Mechanisms of sprouting in the adult central nervous system: cellular responses in areas of terminal degeneration and reinnervation in the rat hippocampus. **1994**, 58, 705-25		92
633	Acidic FGF expression in the surroundings of senile plaques. **1994**, 174, 279-93		14
632	Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. **1995**, 40, 478-93		226
631	Chemotaxis and accumulation of nerve growth factor by microglia and macrophages. **1995**, 41, 594-602		36
630	Inflammatory reaction in experimental autoimmune encephalomyelitis (EAE) is accompanied by a microglial expression of the beta A4-amyloid precursor protein (APP). **1995**, 14, 209-15		31
629	A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques. **1995**, 90, 493-503		25
628	Demonstration of fibroblast growth factor receptor-I in human prostate by polymerase chain reaction and immunohistochemistry. **1995**, 27, 141-7		18
627	Glial expression of the beta-amyloid precursor protein (APP) in global ischemia. **1995**, 15, 647-54		84

626	Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. **1995**, 691, 235-8	49
625	Expression of non-angiotensin II -125I-CGP 42112 binding sites on activated microglia after kainic acid induced neurodegeneration. **1995**, 702, 153-61	15
624	Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte. **1995**, 15, 7712-26	131
623	Maintenance and Regulation in Brain of Neurotransmission, Trophic Factors, and Immune Responses. **1995**, 345-362	1
622	The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. **1995**, 21, 195-218	1110
621	Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. **1995**, 27, 119-37	209
620	Peripheral blood lymphocyte subset distribution and function in patients with Alzheimer's disease and other dementias. **1995**, 25, 212-7	14
619	Amyloid beta protein (A beta) removal by neuroglial cells in culture. **1995**, 16, 737-45	178
618	Role of microglia in senile plaque formation. **1995**, 16, 797-804	165
617	The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. **1996**, 17, 673-80	170
616	Inflammation and Alzheimer's disease pathogenesis. **1996**, 17, 681-6	374
615	Glycation and microglial reaction in lesions of Alzheimer's disease. **1996**, 17, 733-43	75
614	Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. **1996**, 142, 89-102	31
613	Regenerative failure: a potential mechanism for neuritic dystrophy in Alzheimer's disease. **1996**, 142, 103-10	33
612	Lewy body diseases: possible new directions in prophylaxis and therapy. **1996**, 46, 222-4	1
611	Expression of CD43 in human microglia and its downregulation in Alzheimer's disease. **1996**, 71, 81-6	11
610	Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. **1996**, 16, 6021-37	239
609	Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins. **1996**, 707, 196-205	59

608	Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. **1996**, 712, 122-6	126
607	IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells. **1996**, 723, 231-4	41
606	Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. **1996**, 735, 159-68	188
605	Species differences in the generation of reactive oxygen species by microglia. **1996**, 28, 15-20	89
604	Inflammation and Alzheimer disease. **1996**, 28, 83-8	49
603	Microglial cerebrospinal fluid antibodies. Significance for Alzheimer disease. **1996**, 28, 89-95	6
602	Enhancement of immunoreactivity for NF-kappa B in human cerebral infarctions. **1996**, 739, 343-9	84
601	Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. **1996**, 6, 259-74	621
600	Expression of the activation marker urokinase plasminogen-activator receptor in cultured human central nervous system microglia. **1996**, 45, 392-9	34
599	The controversy surrounding the pathogenesis of the multiple sclerosis lesion. **1997**, 72, 665-78	30
598	Apoptosis, neurotrophic factors and neurodegeneration. **1997**, 8, 223-65	38
597	Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease. **1997**, 43, 95-108	37
596	The Controversy Surrounding the Pathogenesis of the Multiple Sclerosis Lesion. **1997**, 72, 665-678	34
595	Risk of Alzheimer's disease and duration of NSAID use. **1997**, 48, 626-32	954
594	Enriched immune-environment of blood-brain barrier deficient areas of normal adult rats. **1997**, 76, 117-31	38
593	Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. **1997**, 78, 152-61	54
592	Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds. **1997**, 80, 6-12	31
591	Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. **1997**, 18, 415-21	204

590	[Physical trauma and multiple sclerosis]. **1997**, 68, 940-4	6
589	Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. **1997**, 41, 200-9	120
588	Adhesion molecule expression on phagocytic microglial cells following anterograde degeneration of perforant path axons. **1997**, 7, 341-9	60
587	Brain inflammatory response induced by intracerebroventricular infusion of lipopolysaccharide: an immunohistochemical study. **1998**, 794, 211-24	96
586	Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. **1998**, 54, 1-6	160
585	Altered expression of immune-related antigens by neuronophages does not improve neuronal survival after severe lesion of the facial nerve in rats. **1998**, 24, 155-171	8
584	Neuroimmunological correlates of cognitive impairment. **1998**, 19, S418-S423	
583	Cell adhesion molecules in neural plasticity and pathology: similar mechanisms, distinct organizations?. **1998**, 55, 659-69	93
582	Molecular cloning of the cDNA coding sequence of IL-2 receptor-gamma (gammac) from human and murine forebrain: expression in the hippocampus in situ and by brain cells in vitro. **1998**, 53, 152-62	31
581	Microglial expression of MHC class II increases in normal aging of nonhuman primates. **1998**, 19, 47-55	207
580	Alzheimer's disease: genetic studies and transgenic models. **1998**, 32, 461-93	349
579	Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease. **1998**, 95, 203-36	36
578	Rat microglia exhibit increased density on Alzheimer's plaques in vitro. **1998**, 149, 42-50	6
577	Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. **1998**, 149, 329-40	188
576	HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. **1998**, 161, 66-9	15
575	Glucocorticoids in Alzheimer's disease. The story so far. **1998**, 12, 1-6	28
574	Production, regulation and role of nitric oxide in glial cells. **1998**, 7, 239-55	35
573	Chapter 24 Neurodegenerative Alzheimer-like pathology in PDAPP 717V-F transgenic mice. **1998**, 117, 327-334	29

572	Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. **1998**, 18, 8126-32	438
571	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. **1998**, 3, d436-46	18
570	Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. **1999**, 96, 9409-14	264
569	Inflammatory responses to amyloid fibrils. **1999**, 309, 723-33	7
568	Effects of melatonin on macrophages/microglia in postnatal rat brain. **1999**, 26, 158-68	46
567	Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. **1999**, 19, 223-30	242
566	Cytoskeletal pathology in familial cerebral amyloid angiopathy (British type) with non-neuritic amyloid plaque formation. **1999**, 97, 170-6	52
565	Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. **1999**, 97, 383-92	69
564	Genetics of neuroinflammation in Alzheimer disease. **1999**, 2, 135-6	4
563	Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. **1999**, 815, 36-43	74
562	Estrogen and microglia: A regulatory system that affects the brain. **1999**, 40, 484-96	117
561	Nonsteroidal Anti-Inflammatory Drugs and Alzheimer Disease. **1999**, 11, 207-224	9
560	Microglia and the immune pathology of Alzheimer disease. **1999**, 65, 13-8	130
559	The effects of a novel NSAID on chronic neuroinflammation are age dependent. **1999**, 20, 305-13	126
558	Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. **1999**, 20, 581-9	273
557	Increased microglial activation and protein nitration in white matter of the aging monkey. **1999**, 20, 395-405	178
556	Microglia as mediators of inflammatory and degenerative diseases. **1999**, 22, 219-40	863
555	Antimicroglia antibodies in sera of Alzheimer's disease patients. **1999**, 45, 508-11	5

554	Microglia in Alzheimer's disease and transgenic models. How close the fit?. **1999**, 154, 1627-31	34
553	Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. **1999**, 6, 167-79	114
552	Intrathecal release of nitric oxide in Alzheimer's disease and vascular dementia. **2000**, 11, 322-6	14
551	Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. **2000**, 67, 109-16	64
550	Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. **2000**, 74, 1017-25	162
549	Activated microglia in dementia with Lewy bodies. **2000**, 55, 132-4	83
548	TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD. **2000**, 54, 2077-81	46
547	Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. **2000**, 57, 817-22	56
546	Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. **2000**, 57, 831-6	57
545	Advances in Research on Neurodegeneration. **2000**,	0
544	Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. **2000**, 275, 16941-7	50
543	Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. **2000**, 97, 10954-9	321
542	A possible model of senile plaques using synthetic amyloid beta-protein and rat glial culture. **2000**, 162, 51-60	14
541	The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. **2000**, 62, 633-48	319
540	Inflammation in Alzheimer's disease: a view from the periphery. **2000**, 21, 437-40; discussion 451-3	18
539	Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. **2000**, 21, 797-806	77
538	Part III. Neuropathology of Alzheimer's disease. **2000**, 46, 687-705	3
537	Cellular and molecular mechanisms of Alzheimer's disease inflammation. **2001**, 3-49	

536	An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. **2001**, 38, 557-65		68
535	Inflammation, autotoxicity and Alzheimer disease. **2001**, 22, 799-809		413
534	Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. **2001**, 22, 957-66		127
533	Apolipoprotein E acts to increase nitric oxide production in macrophages by stimulating arginine transport. **2001**, 1535, 134-44		26
532	Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. **2001**, 1, 53-60		13
531	Molecular and cellular mediators of Alzheimer's disease inflammation. *Journal of Alzheimer's Disease*, **2001**, 3, 131-157	4.3	42
530	Activation mechanism of brain microglia in patients with diffuse neurofibrillary tangles with calcification: a comparison with Alzheimer disease. **2001**, 15, 45-50		8
529	Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. **2001**, 58, 517-9		8
528	Patrick L. McGeer and Edith Graef McGeer. **2001**, 3, 330-365		
527	Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. **2001**, 12, 314-7		36
526	Diffuse Lewy Body Disease. **2001**, 3, 507-518		44
525	Central nervous system in cerebral malaria: 'Innocent bystander' or active participant in the induction of immunopathology?. **2001**, 79, 101-20		54
524	Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. **2001**, 103, 166-74		65
523	Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. **2001**, 14, 474-82		87
522	Intracellular pathways involved in TNF-alpha and superoxide anion release by Abeta(1-42)-stimulated primary human macrophages. **2001**, 115, 144-51		18
521	Genetic requirement of p47phox for superoxide production by murine microglia. **2001**, 15, 285-7		53
520	Activation of human macrophages by amyloid-beta is attenuated by astrocytes. **2001**, 166, 6869-76		45
519	Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. **2002**, 11, 1343-50		126

518	Inflammation in neurodegenerative disease--a double-edged sword. **2002**, 35, 419-32	927
517	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. **2002**, 23, 485-508	159
516	APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. **2002**, 23, 777-85	98
515	Concern over the amyloid vaccine: amyloid heterogeneity and Fc receptor signaling. **2002**, 23, 667-70; discussion 683-4	1
514	Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. **2002**, 112, 7-11	196
513	Chapter 4. Emerging themes in Alzheimer's disease research: Paradigm shift in drug discovery. **2002**, 37, 31-40	1
512	Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. **2002**, 127, 160-8	109
511	Development of antiinflammatory therapy for Alzheimer's disease. **2002**, 56, 421-427	4
510	Age-dependent myelin degeneration and proteolysis of oligodendrocyte proteins is associated with the activation of calpain-1 in the rhesus monkey. **2003**, 84, 157-68	69
509	Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. **2002**, 15, 991-8	300
508	Serotonin acts as a radical scavenger and is oxidized to a dimer during the respiratory burst of activated microglia. **1997**, 69, 2096-101	39
507	Inflammatory signals induce neurotrophin expression in human microglial cells. **1998**, 70, 699-707	220
506	Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. **2003**, 106, 518-26	490
505	Inflammation markers in relation to cognition in a healthy aging population. **2003**, 134, 142-50	224
504	Levation of serum macrophage colony stimulating factor level in patients with Alzheimer's disease. **2003**, 32, 61-69	0
503	The impact of systemic infection on the progression of neurodegenerative disease. **2003**, 4, 103-12	341
502	Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. **2003**, 63, 731-9	48
501	Neurotrophins regulate proliferation and survival of two microglial cell lines in vitro. **2003**, 183, 469-81	83

500	Is there a future for vaccination as a treatment for Alzheimer's disease?. **2003**, 24, 391-5		34
499	Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. **2003**, 61, 255-60		174
498	Do infectious agents play a role in dementia?. **2003**, 11, 312-7		46
497	Intrathecal inflammation precedes development of Alzheimer's disease. **2003**, 74, 1200-5		295
496	CD36 mediates the innate host response to beta-amyloid. **2003**, 197, 1657-66		349
495	Targeting monocyte chemoattractant protein-1 signalling in disease. **2003**, 7, 35-48		110
494	Cerebrospinal fluid and serum antimicroglial antibodies: prospects for early diagnosis of Alzheimer's disease. **2003**, 3, 247-57		3
493	IL-10 and glucocorticoids inhibit Abeta(1-42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. *Journal of Alzheimer's Disease*, **2003**, 5, 105-17	4.3	43
492	APOE genotype-specific differences in human and mouse macrophage nitric oxide production. **2004**, 147, 62-7		65
491	Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. **2004**, 1022, 19-29		43
490	Microglia and Alzheimer's disease pathogenesis. **2004**, 77, 1-8		255
489	Microglia and neuroinflammation: a pathological perspective. **2004**, 1, 14		664
488	Early complement activation increases in the brain in some aged normal subjects. **2004**, 25, 1001-7		16
487	Alzheimer's disease pathogenesis and therapeutic interventions. **2004**, 11, 456-67		291
486	Neurochemical imaging of dementias. **2004**, 34, 70-82		16
485	Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. *Journal of Alzheimer's Disease*, **2004**, 6, 147-57	4.3	116
484	Proteases and Alzheimer's Disease: Present Knowledge and Emerging Concepts of Therapy. **2005**, 1-23		5
483	Alzheimer's associated inflammation, potential drug targets and future therapies. **2005**, 112, 429-53		82

482	Mechanism of amyloid peptide induced CCR5 expression in monocytes and its inhibition by siRNA for Egr-1. **2005**, 289, C264-76		22
481	Chronically active: activation of microglial proteolysis in ageing and neurodegeneration. **2005**, 10, 207-13		8
480	Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. **2005**, 2, 355-65		124
479	Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. **2005**, 25, 1904-13		567
478	Cytokines and Brain. **2005**, 41-80		0
477	Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. **2005**, 76, 77-98		1162
476	Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. **2005**, 2, 22		206
475	Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. **2006**, 3, 27		317
474	Peripheral infection and aging interact to impair hippocampal memory consolidation. **2006**, 27, 723-32		258
473	The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. **2006**, 27, 691-701		31
472	Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. **2006**, 22, 95-102		86
471	Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. *Journal of Alzheimer's Disease*, **2006**, 9, 271-6	4.3	203
470	Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. *Molecular Psychiatry*, **2006**, 11, 1032-48	15.1	84
469	The significance of neuroinflammation in understanding Alzheimer's disease. **2006**, 113, 1685-95		216
468	Alpha-tocopherol (vitamin E) induces rapid, nonsustained proliferation in cultured rat microglia. **2006**, 53, 669-74		19
467	Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease. **2006**, 12, 719-38		28
466	Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach. **2006**, 3, 81-112		2
465	Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. **2006**, 38, 333-47		433

464	Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. **2007**, 5, 232-43	44
463	Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. **2007**, 117, 1595-604	295
462	Effects of Alzheimer's peptide and alpha1-antichymotrypsin on astrocyte gene expression. **2007**, 28, 51-61	10
461	NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. **2007**, 28, 639-47	397
460	Alzheimer's disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. **2007**, 68, 378-88	59
459	Role of complement in neurodegeneration and neuroinflammation. **2007**, 44, 999-1010	245
458	Pharmacological Mechanisms in Alzheimer's Therapeutics. **2007**,	1
457	Die Rolle des Immunsystems bei der Alzheimer-Demenz. **2007**, 26, 867-875	
456	Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. **2007**, 13, 432-8	674
455	Systemic infections and inflammation affect chronic neurodegeneration. **2007**, 7, 161-7	747
454	Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. **2007**, 8, 57-69	2906
453	Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. **2007**, 103, 67-76	18
452	Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. **2008**, 104, 524-33	128
451	Chlorinative stress: an under appreciated mediator of neurodegeneration?. **2007**, 19, 219-28	418
450	Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process. **2007**, 42, 355-63	12
449	Interleukin-1 alpha polymorphism has influence on late-onset sporadic Parkinson's disease in Taiwan. **2007**, 114, 1173-7	12
448	Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. **2007**, 114, 243-54	18
447	New developments in understanding and treating neuroinflammation. **2008**, 86, 975-85	38

446	Blockade of chloride intracellular ion channel 1 stimulates Abeta phagocytosis. **2008**, 86, 2488-98		19
445	Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. **2008**, 56, 1091-103		71
444	Vitamin E increases S100B-mediated microglial activation in an S100B-overexpressing mouse model of pathological aging. **2008**, 56, 1780-90		22
443	NADPH oxidase as a therapeutic target in Alzheimer's disease. **2008**, 9 Suppl 2, S8		127
442	Microglia and myeloperoxidase: a deadly partnership in neurodegenerative disease. **2008**, 45, 726-31		88
441	Cognitive and neuroinflammatory consequences of mild repeated stress are exacerbated in aged mice. **2008**, 33, 755-65		93
440	Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. **2008**, 28, 8354-60		861
439	The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. **2008**, 5, 7		312
438	All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. **2008**, 64, 891-5		19
437	Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. **2008**, 29, 626-32		141
436	Biology and neuropathology of dementia in syphilis and Lyme disease. **2008**, 89, 825-44		26
435	Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. **2008**, 22, 1491-501		147
434	Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. **2008**, 181, 7194-204		101
433	Adhesion of exogenous human microglia and THP-1 cells to amyloid plaques of postmortem Alzheimer's disease brain. *Journal of Alzheimer's Disease*, **2008**, 14, 345-52	4.3	18
432	Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. *Journal of Alzheimer's Disease*, **2008**, 14, 147-59	4.3	87
431	Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. **2008**, 1, 29-39		32
430	The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. *Journal of Alzheimer's Disease*, **2008**, 15, 571-87	4.3	66
429	Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. **2009**, 18, 3876-93		44

428	Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?. **2009**, 9, 307-30		28
427	Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. **2009**, 66, 60-7		130
426	Manganese induces dopaminergic neurodegeneration via microglial activation in a rat model of manganism. **2009**, 107, 156-64		114
425	Immune and behavioral consequences of microglial reactivity in the aged brain. **2009**, 49, 254-66		42
424	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. **2009**, 34, 163-77		204
423	Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. **2009**, 34, 525-34		107
422	Oligomeric amyloid-beta(1-42) induces THP-1 human monocyte adhesion and maturation. **2009**, 1254, 109-19		12
421	Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. **2009**, 118, 475-85		456
420	Inflammation and microglia actions in Alzheimer's disease. **2009**, 4, 380-8		41
419	Does neuroinflammation fan the flame in neurodegenerative diseases?. **2009**, 4, 47		505
418	Current Hypotheses and Research Milestones in Alzheimer's Disease. **2009**,		1
417	Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection. **2009**, 23, 46-54		176
416	Amyloid beta peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. **2009**, 30, 210-21		20
415	Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. *Journal of Alzheimer's Disease*, **2009**, 16, 787-808	4.3	45
414	Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line. **2009**, 48, 9011-21		16
413	Complexity of microglial activation state: can modifying microglial activation treat Alzheimer's disease?. **2009**, 4, 137-139		
412	Subcellular Fate of Nanodelivery Systems. **2010**, 93-121		
411	Manipulating phagocyte activity in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 20, 441-3	4.3	1

410	Role of microglia in neurotrauma. **2010**, 7, 366-77		462
409	Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. **2010**, 120, 369-84		105
408	Membrane biophysics and mechanics in Alzheimer's disease. *Molecular Neurobiology*, **2010**, 41, 138-48	6.2	40
407	Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. **2010**, 220, 34-42		53
406	Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. **2010**, 22, 977-83		192
405	Kynurenines, neurodegeneration and Alzheimer's disease. **2010**, 14, 2045-54		46
404	Microglial activation and chronic neurodegeneration. **2010**, 7, 354-65		611
403	Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. **2010**, 112, 1099-114		180
402	Altered microglial copper homeostasis in a mouse model of Alzheimer's disease. **2010**, 114, 1630-8		63
401	A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. **2010**, 20, 138-53		70
400	Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. **2010**, 3, 1812-1841		53
399	Staging anti-inflammatory therapy in Alzheimer's disease. *Frontiers in Aging Neuroscience*, **2010**, 2, 142	5.3	27
398	Secretory phospholipase A2 type III enhances alpha-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. **2010**, 51, 957-66		27
397	Reimagining Alzheimer's disease--an age-based hypothesis. **2010**, 30, 16755-62		267
396	Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. **2010**, 30, 9228-40		86
395	Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. **2010**, 7, 255-61		25
394	Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. **2010**, 17, 391-406		63
393	Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. **2010**, 1, e1		68

392	Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history. *Frontiers in Aging Neuroscience*, **2010**, 2, 22	5.3	55
391	Microglia and neuroprotection: from in vitro studies to therapeutic applications. **2010**, 92, 293-315		189
390	CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer's disease. **2010**, 176, 261-4		12
389	Recent developments in the inhibitors of neuroinflammation and neurodegeneration: inflammatory oxidative enzymes as a drug target. **2010**, 20, 1531-46		17
388	Animal Models of Dementia. **2011**,		7
387	Oxidative Stress and Free Radical Damage in Neurology. **2011**,		16
386	CXCL8 protects human neurons from amyloid-β-induced neurotoxicity: relevance to Alzheimer's disease. **2011**, 412, 565-71		27
385	The beneficial role of vitamin D in Alzheimer's disease. **2011**, 26, 511-20		20
384	Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing. **2011**, 58, 321-9		128
383	Metabolic, immune, epigenetic, endocrine and phenotypic abnormalities found in individuals with autism spectrum disorders, Down syndrome and Alzheimer disease may be caused by congenital and/or acquired chronic cerebral toxoplasmosis. **2011**, 5, 14-59		19
382	Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to aβ-Peptide-induced membrane changes. **2011**, 2011, 134971		16
381	Glial cells in amyotrophic lateral sclerosis. **2011**, 2011, 718987		73
380	History of innate immunity in neurodegenerative disorders. **2011**, 2, 77		38
379	Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. **2011**, 3, 249-58		36
378	The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. **2011**, 8, 142-50		82
377	Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-β1-42 oligomer-injected mice. *Journal of Alzheimer's Disease*, **2011**, 23, 147-59	4.3	107
376	Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. *Journal of Alzheimer's Disease*, **2011**, 27, 1-10	4.3	34
375	Microglial alterations in human Alzheimer's disease following Aβ42 immunization. **2011**, 37, 513-24		72

374	Sensing damage by the NLRP3 inflammasome. **2011**, 243, 152-62		203
373	Cytokines and neuronal channels: a molecular basis for age-related decline of neuronal function?. **2011**, 46, 199-206		33
372	Microglia demonstrate age-dependent interaction with amyloid-fibrils. *Journal of Alzheimer's Disease*, **2011**, 25, 279-93	4.3	110
371	Microglial pathology in Down syndrome. **2011**, 122, 455-66		46
370	Effects of collagen-induced rheumatoid arthritis on amyloidosis and microvascular pathology in APP/PS1 mice. **2011**, 12, 106		16
369	Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. **2011**, 8, 90		188
368	Inflammation, mitochondria, and the inhibition of adult neurogenesis. **2011**, 89, 1989-96		82
367	Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment?. **2011**, 8, 164-74		77
366	Histological and direct evidence for the role of complement in the neuroinflammation of AD. **2011**, 8, 34-58		57
365	CD45 deficiency drives amyloid-peptide oligomers and neuronal loss in Alzheimer's disease mice. **2011**, 31, 1355-65		65
364	Emerging roles of pathogens in Alzheimer disease. **2011**, 13, e30		119
363	Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. **2012**, 2012, 170276		60
362	Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. **2012**, 2012, 946813		47
361	Polymorphisms in neuropsychiatric and neuroinflammatory disorders and the role of next generation sequencing in early diagnosis and treatment. **2012**, 89, 85-116		1
360	Amyloid-oligomers stimulate microglia through a tyrosine kinase dependent mechanism. **2012**, 33, 2247-61		69
359	Transcriptome analysis of amoeboid and ramified microglia isolated from the corpus callosum of rat brain. **2012**, 13, 64		63
358	Tumor necrosis factor-synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. **2012**, 9, 106		140
357	Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. **2012**, 9, 117		61

356	The changing phenotype of microglia from homeostasis to disease. **2012**, 1, 9		132
355	Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. **2012**, 26, 1191-201		430
354	Isolated amyloid-β(1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. **2012**, 3, 302-11		47
353	Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. **2012**, 7, e37917		54
352	Current understanding of the glial response to disorders of the aging CNS. **2012**, 3, 95		4
351	Alzheimer's disease, neuroprotection, and CNS immunosenescence. **2012**, 3, 138		32
350	Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. **2012**, 2012, 489456		98
349	A review: inflammatory process in Alzheimer's disease, role of cytokines. **2012**, 2012, 756357		502
348	Alzheimer's disease and the "Valley Of Death": not enough guidance from human brain tissue?. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S219-33	4.3	18
347	Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. **2012**, 287, 6912-27		118
346	Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. **2012**, 69, 2409-27		94
345	Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. **2012**, 120, 292-301		144
344	Network medicine in drug design: implications for neuroinflammation. **2012**, 17, 600-7		14
343	A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. **2013**, 182, 2332-44		102
342	Protective effects of bilobalide on A(25-35) induced learning and memory impairments in male rats. **2013**, 106, 77-84		46
341	Amyloid-β(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. **2013**, 8, 312-22		22
340	Neurodegeneration from Drugs and Aging-Derived Free Radicals. **2013**, 237-310		2
339	The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms. **2013**, 28, 427-39		16

338	Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. **2013**, 10, 84		127
337	Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. **2013**, 5, 113-39		166
336	Increased densities of resting and activated microglia in the dentate gyrus follow senile plaque formation in the CA1 subfield of the hippocampus in the triple transgenic model of Alzheimer's disease. *Neuroscience Letters*, **2013**, 552, 129-34	3.3	24
335	Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. **2013**, 124, 59-68		82
334	Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. **2013**, 39, 69-85		42
333	Exercise protects against chronic restraint stress-induced oxidative stress in the cortex and hippocampus. **2013**, 1509, 66-78		26
332	Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. **2013**, 33, 5053-64		246
331	Blockage of CR1 prevents activation of rodent microglia. **2013**, 54, 139-49		57
330	Microglia actions in Alzheimer's disease. **2013**, 126, 461-77		209
329	Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. **2013**, 136, 2677-96		165
328	MRI reveals differential effects of amphetamine exposure on neuroglia in vivo. **2013**, 27, 712-24		12
327	Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease. **2013**, 143, 597-605		84
326	Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. *Journal of Alzheimer's Disease*, **2013**, 35, 697-713	4.3	150
325	Amniotic fluid stem cells with low β-interferon response showed behavioral improvement in Parkinsonism rat model. **2013**, 8, e76118		9
324	Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment?. **2013**, 13, 1879-904		16
323	The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. **2013**, 2013, 860959		29
322	Neuroprotective Properties of a Standardized Extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as Evaluated by a Parkinson's Disease Model in Rats. **2014**, 2014, 519615		16
321	The Alzheimer pandemic: is paracetamol to blame?. **2014**, 13, 2-14		4

320	The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment. **2014**, 9, 50	19
319	Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases. **2014**, 2014, 465694	56
318	Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. **2014**, 37, 441-8	98
317	Damage of neuroblastoma cell SH-SY5Y mediated by MPP+ inhibits proliferation of T-cell leukemia Jurkat by co-culture system. **2014**, 15, 10738-50	4
316	Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain. **2014**, 62, 96-105	16
315	Neuroinflammation and □amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging. **2014**, 37, 1-18	19
314	Respiratory infection promotes T cell infiltration and amyloid-□deposition in APP/PS1 mice. **2014**, 35, 109-21	89
313	Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. **2014**, 88, 565-72	54
312	PrP106-126 and A□1-42 peptides induce BV-2 microglia chemotaxis and proliferation. **2014**, 52, 107-16	4
311	Microglial dysfunction in brain aging and Alzheimer's disease. **2014**, 88, 594-604	352
310	Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. **2014** , 40, 23-32	80
309	Enhanced brain distribution of modified aspartoacylase. **2014**, 113, 219-24	2
308	CD47 does not mediate amyloid-□(1-42) protofibril-stimulated microglial cytokine release. **2014**, 454, 239-44	7
307	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. **2014**, 35, 338-48	100
306	Human APOE4 increases microglia reactivity at A□plaques in a mouse model of A□deposition. **2014**, 11, 111	104
305	Microglia as a critical player in both developmental and late-life CNS pathologies. **2014**, 128, 333-45	52
304	The role of microglia in human disease: therapeutic tool or target?. **2014**, 128, 363-80	89
303	Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease. **2014**, 11, 84	11

302	BioAge: toward a multi-determined, mechanistic account of cognitive aging. *Ageing Research Reviews*, **2014**, 18, 95-105	12	25
301	Amyloid-β(1-42) protofibrils stimulate a quantum of secreted IL-1β despite significant intracellular IL-1β accumulation in microglia. **2014**, 1842, 2276-85		22
300	Human CNS immune senescence and neurodegeneration. **2014**, 29, 93-6		65
299	The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. **2014**, 141, 292-301		49
298	Cyclooxygenase I and II inhibitors distinctly enhance hippocampal- and cortex-dependent cognitive functions in mice. **2015**, 12, 7649-56		12
297	Overexpression of mutant amyloid-β protein precursor and presenilin 1 modulates enteric nervous system. *Journal of Alzheimer's Disease*, **2015**, 44, 1263-78	4.3	44
296	Schisandrin C Ameliorates Learning and Memory Deficits by Aβ-induced Oxidative Stress and Neurotoxicity in Mice. **2015**, 29, 1373-1380		36
295	Dissecting Alzheimer disease in Down syndrome using mouse models. **2015**, 9, 268		29
294	Therapeutic potential of mGluR5 targeting in Alzheimer's disease. *Frontiers in Neuroscience*, **2015**, 9, 215	5.1	53
293	T Cells-Protective or Pathogenic in Alzheimer's Disease?. **2015**, 10, 547-60		30
292	Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease. **2015**, 96, 29-41		239
291	Implication of matrix metalloproteinases in regulating neuronal disorder. **2015**, 42, 1-11		23
290	Neuromelanin activates proinflammatory microglia through a caspase-8-dependent mechanism. **2015**, 12, 5		25
289	TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. **2015**, 160, 1061-71		847
288	Alternatively activated microglia and macrophages in the central nervous system. **2015**, 131, 65-86		395
287	Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. **2015**, 35, 5969-82		118
286	Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?. **2015**, 28, 148-54		31
285	Aβ amyloid, microglia, and the inflammasome in Alzheimer's disease. *Seminars in Immunopathology*, **2015**, 37, 607-11	12	114

284	In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice. **2015**, 35, 15716-30		77
283	Microglial A receptors in Alzheimer's disease. **2015**, 35, 71-83		136
282	Insufficient resolution response in the hippocampus of a senescence-accelerated mouse model--SAMP8. **2015**, 55, 396-405		19
281	Valproic acid alleviates memory deficits and attenuates amyloid- deposition in transgenic mouse model of Alzheimer's disease. *Molecular Neurobiology*, **2015**, 51, 300-12	6.2	53
280	Microglial response to Alzheimer's disease is differentially modulated by voluntary wheel running and enriched environments. **2015**, 220, 941-53		29
279	A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-Driven Inflammation in Down Syndrome. **2016**, 15, 434-47		20
278	Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. **2016**, 8, 575-88		54
277	Environmental Toxicants-Induced Immune Responses in the Olfactory Mucosa. **2016**, 7, 475		34
276	Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. **2017**, 140, 826-842		60
275	7-Nicotinic Acetylcholine Receptors and Amyloid Peptides in Alzheimer Disease. **2016**, 171-205		1
274	Glial Cells in Health and Disease of the CNS. **2016**,		6
273	Age-Dependent Changes in the Activation and Regulation of Microglia. **2016**, 949, 205-226		35
272	Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin() and (m)VD-hemopressin() on memory in novel object and object location recognition tasks in normal young and A1-42-treated mice. **2016**, 134 Pt B, 264-74		17
271	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. **2016**, 12, 1132-1148		62
270	Amyloid-42 protofibrils are internalized by microglia more extensively than monomers. **2016**, 1648, 485-495		21
269	The human-specific CASP4 gene product contributes to Alzheimer-related synaptic and behavioural deficits. **2016**, 25, 4315-4327		10
268	Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years. *Journal of Alzheimer's Disease*, **2016**, 54, 853-857	4.3	127
267	Inhomogeneous distribution of Iba-1 characterizes microglial pathology in Alzheimer's disease. **2016**, 64, 1562-72		65

266	Compound K derived from ginseng: neuroprotection and cognitive improvement. **2016**, 7, 4506-4515		49
265	Do Microglia Default on Network Maintenance in Alzheimer's Disease?. *Journal of Alzheimer's Disease*, **2016**, 51, 657-69	4.3	16
264	Reprint of: Microglial toll-like receptors and Alzheimer's disease. **2016**, 55, 166-178		9
263	Retinal and Optic Nerve Damage is Associated with Early Glial Responses in an Experimental Autoimmune Glaucoma Model. **2016**, 58, 470-82		49
262	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. **2016**, 46, 57-87		11
261	Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase A2 Phagocytosis. *Molecular Neurobiology*, **2016**, 53, 2733-49	6.2	113
260	Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease. **2016**, 53, 166-83		8
259	Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats. **2016**, 94, 819-28		26
258	Microglia in dementia with Lewy bodies. **2016**, 55, 191-201		32
257	Microglial toll-like receptors and Alzheimer's disease. **2016**, 52, 187-198		43
256	Microglia in Health and Disease. **2015**, 8, a020560		160
255	Histamine Receptors as Drug Targets. **2017**,		
254	Cerebrospinal Fluid Markers in Neuroinflammation: The Paradigm of Optic Neuritis. **2017**, 411-431		1
253	Role of neuroinflammation in neurodegeneration: new insights. **2017**, 9, 14		151
252	TREM2, Microglia, and Neurodegenerative Diseases. **2017**, 23, 512-533		199
251	Should We Stop Saying 'Glia' and 'Neuroinflammation'?. **2017**, 23, 486-500		58
250	NF-B dependent up-regulation of TRPC6 by A in BV-2 microglia cells increases COX-2 expression and contributes to hippocampus neuron damage. *Neuroscience Letters*, **2017**, 651, 1-8	3.3	23
249	Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease. **2017**, 292, 11310-11325		29

248	Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease. **2017**, 356, 44-51	14
247	Concurrent suppression of NF-B, p38 MAPK and reactive oxygen species formation underlies the effect of a novel compound isolated from Curcuma comosa Roxb. in LPS-activated microglia. **2017**, 69, 917-924	6
246	Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease. **2017**, 37, 637-647	225
245	Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?. **2017**, 38, 956-966	93
244	Ginkgolide B Suppresses Methamphetamine-Induced Microglial Activation Through TLR4-NF-B Signaling Pathway in BV2 Cells. **2017**, 42, 2881-2891	17
243	Synaptotagmin-11 inhibits cytokine secretion and phagocytosis in microglia. **2017**, 65, 1656-1667	17
242	Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4). **2017**, 56, 117-163	14
241	TLR4 is a link between diabetes and Alzheimer's disease. **2017**, 316, 234-244	67
240	Changes in neocortical and hippocampal microglial cells during hibernation. **2018**, 223, 1881-1895	6
239	The Endocannabinoid System and Human Brain Functions. **2017**, 115-186	3
238	47th Annual Meeting of the German Society for Immunology, 12-15 September, 2017, Erlangen, Germany. **2017**, 47 Suppl 2, 1-333	1
237	Impaired Resolution of Inflammation in Alzheimer's Disease: A Review. **2017**, 8, 1464	51
236	Rescue of Neurons by Resolving Inflammation. **2017**, 175-192	
235	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. **2017**, 108, 307-323	46
234	Old and new inflammation and infection hypotheses of Alzheimer's disease: focus on Microglia-aging for chronic neuroinflammation. **2017**, 150, 141-147	2
233	Microglia in Alzheimer's disease. **2017**, 127, 3240-3249	384
232	Atrophy and microglial distribution in primary progressive aphasia with transactive response DNA-binding protein-43 kDa. **2018**, 83, 1096-1104	11
231	Neuroprotective Effect of Alpha-Linolenic Acid against AMediated Inflammatory Responses in C6 Glial Cell. **2018**, 66, 4853-4861	14

230	Neuroinflammatory responses in Alzheimer's disease. **2018**, 125, 771-779		71
229	Decreased microglial numbers in Vav1-Cre:dicer knock-out mice suggest a second source of microglia beyond yolk sac macrophages. **2018**, 218, 190-198		9
228	Conquering Alzheimer's Disease by Self Treatment. *Journal of Alzheimer's Disease*, **2018**, 64, S361-S363	4.3	4
227	NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. *Molecular Neurobiology*, **2018**, 55, 1977-1987	6.2	107
226	Innate immunity in Alzheimer's disease: the relevance of animal models?. **2018**, 125, 827-846		10
225	Let's make microglia great again in neurodegenerative disorders. **2018**, 125, 751-770		14
224	Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far?. **2018**, 23, e12454		62
223	Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review. *Molecular Psychiatry*, **2018**, 23, 177-198	15.1	195
222	Alzheimer's Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs. *Journal of Alzheimer's Disease*, **2018**, 62, 1219-1222	4.3	37
221	Defining Microglial Phenotypes in Alzheimer's Disease. **2018**,		
220	Microglial activation occurs late during preclinical Alzheimer's disease. **2018**, 66, 2550-2562		38
219	Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer's Disease. **2018**, 2018, 2530414		34
218	Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model. **2018**, 13, 65		29
217	New insights into the role of TREM2 in Alzheimer's disease. **2018**, 13, 66		161
216	Inflammation: Bridging Age, Menopause and APOE4 Genotype to Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2018**, 10, 312	5.3	31
215	Anti-41 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer's Disease. **2018**, 15, 1123-1135		8
214	Microglial signatures and their role in health and disease. **2018**, 19, 622-635		287
213	Royal Jelly Attenuates LPS-Induced Inflammation in BV-2 Microglial Cells through Modulating NF-B and p38/JNK Signaling Pathways. **2018**, 2018, 7834381		39

212	Lauric Acid Alleviates Neuroinflammatory Responses by Activated Microglia: Involvement of the GPR40-Dependent Pathway. **2018**, 43, 1723-1735		15
211	Immunosenescence - the role in the immunotherapy of older population. **2018**, 119, 217-220		3
210	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. **2018**, 91, e867-e877		120
209	Neuroinflammation: Microglia and T Cells Get Ready to Tango. **2017**, 8, 1905		149
208	Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. **2017**, 10, 421		108
207	Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. **2018**, 19,		51
206	Iridoids and Other Monoterpenes in the Alzheimer's Brain: Recent Development and Future Prospects. **2018**, 23,		29
205	Can inflammation be resolved in Alzheimer's disease?. **2018**, 11, 1756286418791107		28
204	Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease. **2018**, 27, 814-830		25
203	Neuro-regeneration Therapeutic for Alzheimer's Dementia: Perspectives on Neurotrophic Activity. **2019**, 40, 655-668		11
202	Alzheimer's Disease Research Using Human Microglia. **2019**, 8,		17
201	Effect of Lactobacillus paracasei A221-fermented ginseng on impaired spatial memory in a rat model with cerebral ischemia and □amyloid injection. **2019**, 6, 96		1
200	The Possible Causal Link of Periodontitis to Neuropsychiatric Disorders: More Than Psychosocial Mechanisms. **2019**, 20,		32
199	Microglial Phenotyping in Neurodegenerative Disease Brains: Identification of Reactive Microglia with an Antibody to Variant of CD105/Endoglin. **2019**, 8,		9
198	Microbiota-gut-brain axis and toll-like receptors in Alzheimer's disease. **2019**, 17, 1309-1317		36
197	Inflammasome-mediated innate immunity in Alzheimer's disease. **2019**, 33, 13075-13084		32
196	Maresin 1 Improves Cognitive Decline and Ameliorates Inflammation in a Mouse Model of Alzheimer's Disease. *Frontiers in Cellular Neuroscience*, **2019**, 13, 466	6.1	22
195	Altered microglia and neurovasculature in the Alzheimer's disease cerebellum. **2019**, 132, 104589		15

194	Is Alzheimer's disease an inflammasomopathy?. *Ageing Research Reviews*, **2019**, 56, 100966	12	43
193	Microglia Biology: One Century of Evolving Concepts. **2019**, 179, 292-311		313
192	Inflammatory mechanisms in neurodegeneration. **2019**, 149, 562-581		49
191	A Fragment of Apolipoprotein E4 Leads to the Downregulation of a CXorf56 Homologue, a Novel ER-Associated Protein, and Activation of BV2 Microglial Cells. **2019**, 2019, 5123565		2
190	CD4 T Cells Induce A Subset of MHCII-Expressing Microglia that Attenuates Alzheimer Pathology. **2019**, 16, 298-311		25
189	Phytomedicine-Based Potent Antioxidant, Fisetin Protects CNS-Insult LPS-Induced Oxidative Stress-Mediated Neurodegeneration and Memory Impairment. **2019**, 8,		21
188	Do Microglial Sex Differences Contribute to Sex Differences in Neurodegenerative Diseases?. **2019**, 25, 741-749		39
187	Activated Microglia in Cortical White Matter Across Cognitive Aging Trajectories. *Frontiers in Aging Neuroscience*, **2019**, 11, 94	5.3	18
186	Gastrodin attenuates proliferation and inflammatory responses in activated microglia through Wnt/ catenin signaling pathway. **2019**, 1717, 190-203		18
185	Late-life environmental enrichment preserves short-term memory and may attenuate microglia in male APP/PS1 mice. **2019**, 408, 282-292		12
184	Immune Signaling in Neurodegeneration. **2019**, 50, 955-974		105
183	Low Cerebrospinal Fluid Levels of Melanotransferrin Are Associated With Conversion of Mild Cognitively Impaired Subjects to Alzheimer's Disease. *Frontiers in Neuroscience*, **2019**, 13, 181	5.1	6
182	Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. **2019**, 10, 1365		108
181	Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease. **2019**, 27, 663-677		129
180	Antioxidants in Alzheimer Therapy. **2019**, 13-18		1
179	Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. **2019**, 116, 25293-25303		55
178	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. *Journal of Alzheimer Disease*, **2019**, 67, 327-341	4.3	20
177	The Evolving Dialogue of Microglia and Neurons in Alzheimer's Disease: Microglia as Necessary Transducers of Pathology. **2019**, 405, 24-34		37

176	Chronic Amyloid □Oligomer Infusion Evokes Sustained Inflammation and Microglial Changes in the Rat Hippocampus via NLRP3. **2019**, 405, 35-46		15
175	Prominent microglial activation in cortical white matter is selectively associated with cortical atrophy in primary progressive aphasia. **2019**, 45, 216-229		11
174	Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. **2020**, 16, 52-69		76
173	Intravitreal S100B Injection Triggers a Time-Dependent Microglia Response in a Pro-Inflammatory Manner in Retina and Optic Nerve. *Molecular Neurobiology*, **2020**, 57, 1186-1202	6.2	9
172	The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease. **2020**, 98, 28-41		109
171	Dystrophic microglia in late-onset Alzheimer's disease. **2020**, 68, 845-854		53
170	Microglia, Lifestyle Stress, and Neurodegeneration. **2020**, 52, 222-240		82
169	Single-Nucleus RNA-Seq Is Not Suitable for Detection of Microglial Activation Genes in Humans. **2020**, 32, 108189		62
168	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. *Frontiers in Aging Neuroscience*, **2020**, 12, 272	5.3	3
167	Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. **2020**, 2, fcaa124		17
166	Dynamic Neuroimmune Profile during Mid-life Aging in the Female Brain and Implications for Alzheimer Risk. **2020**, 23, 101829		4
165	Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. **2020**, 143, 3653-3671		20
164	Diesel exhaust impairs TREM2 to dysregulate neuroinflammation. **2020**, 17, 351		7
163	Microglia: Agents of the CNS Pro-Inflammatory Response. **2020**, 9,		71
162	Quantitative immunohistochemical analysis of myeloid cell marker expression in human cortex captures microglia heterogeneity with anatomical context. **2020**, 10, 11693		11
161	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. **2020**, 10, 267		9
160	Label-free vibrational imaging of different A□plaque types in Alzheimer's disease reveals sequential events in plaque development. **2020**, 8, 222		13
159	Effects of a Nutritional Formulation Containing Caprylic and Capric Acid, Phosphatidylserine, and Docosahexaenoic Acid in Streptozotocin-Lesioned Rats. **2020**, 4, 353-363		3

158	TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment. *Frontiers in Neuroscience*, **2020**, 14, 602508	5.1	9
157	Synergistic depletion of gut microbial consortia, but not individual antibiotics, reduces amyloidosis in APPPS1-21 Alzheimer's transgenic mice. **2020**, 10, 8183		25
156	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. **2020**, 21,		4
155	Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer's disease. **2020**, 9, 1068-1084		54
154	Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. **2020**, 117, 6844-6854		33
153	Trem2 Splicing and Expression are Preserved in a Human A□producing, Rat Knock-in Model of Trem2-R47H Alzheimer's Risk Variant. **2020**, 10, 4122		7
152	Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. **2020**, 46, 623-640		12
151	Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations. **2020**, 13, 1756286420935676		9
150	Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer's Disease Brains. **2020**, 21,		47
149	Microglia and Other Myeloid Cells in Central Nervous System Health and Disease. **2020**, 375, 154-160		12
148	Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. **2020**, 25, 1074-1085		7
147	Accumulation of neurofibrillary tangles and activated microglia is associated with lower neuron densities in the aphasic variant of Alzheimer's disease. **2021**, 31, 189-204		12
146	Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?. **2021**, 17, 157-172		262
145	Role of Neuroinflammation in Neurodegenerative Disorders. **2021**, 41-49		0
144	Human induced pluripotent stem cell□based modeling of Alzheimer□s disease, a glial perspective. **2021**, 21-35		
143	Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease. *Molecular Neurobiology*, **2021**, 58, 2792-2802	6.2	
142	Positive Feedback Regulation of Microglial Glucose Metabolism by Histone H4 Lysine 12 Lactylation in Alzheimer's Disease.		
141	Spatial memory deficiency early in 6xTg Alzheimer's disease mouse model. **2021**, 11, 1334		7

140	Central Nervous System Molecular Imaging. **2021**, 1261-1285		
139	African Medicinal Plants Useful for Cognition and Memory: Therapeutic Implications for Alzheimer Disease. **2021**, 87, 107-134		2
138	The Role of Microglia in Sporadic Alzheimer's Disease. *Journal of Alzheimer s Disease*, **2021**, 79, 961-968	4.3	14
137	Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration. **2021**, 141, 881-899		17
136	Wild radish (Raphanus sativus var. hortensis f. raphanistroides) root extract protects neuronal cells by inhibiting microglial activation. **2021**, 64,		1
135	Investigating the Spatial Associations Between Amyloid- Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer's Disease. *Journal of Alzheimer s Disease*, **2021**, 80, 113-132	4.3	0
134	Interplay Between Microglia and Alzheimer's Disease-Focus on the Most Relevant Risks: APOE Genotype, Sex and Age. *Frontiers in Aging Neuroscience*, **2021**, 13, 631827	5.3	3
133	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. **2021**, 17, 946-958		4
132	Harnessing the immune system for the treatment of Parkinson's disease. **2021**, 1758, 147308		4
131	Knowledge gaps in Alzheimer's disease immune biomarker research. **2021**,		3
130	Microglia in Aging and Alzheimer's Disease: A Comparative Species Review. **2021**, 10,		9
129	Nanomaterials toward the treatment of Alzheimer disease: Recent advances and future trends. **2021**, 32, 1857-1868		9
128	Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer's Disease. **2021**, 19, 908-924		3
127	TREM2 impacts brain microglia, oligodendrocytes and endothelial co-expression modules revealing genes and pathways important in Alzheimer s disease.		
126	The Mechanisms of Sevoflurane-Induced Neuroinflammation. *Frontiers in Aging Neuroscience*, **2021**, 13, 717745	5.3	3
125	Nerve Growth Factor Compromise in Down Syndrome. *Frontiers in Aging Neuroscience*, **2021**, 13, 719507	5.3	
124	Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease. **2021**,		5
123	Sex Differences in Locus Coeruleus: A Heuristic Approach That May Explain the Increased Risk of Alzheimer's Disease in Females. *Journal of Alzheimer s Disease*, **2021**, 83, 505-522	4.3	1

122	A Specialized Nutritional Formulation Prevents Hippocampal Glial Activation and Memory Impairment Induced by Amyloid-Oligomers in Mice. *Journal of Alzheimer's Disease*, **2021**, 83, 1113-1124	4.3	0
121	Oxygen Sensing and Signaling in Alzheimer's Disease: A Breathtaking Story!. **2021**, 1		
120	Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders. **2021**, 12, 871-886		2
119	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. *Frontiers in Aging Neuroscience*, **2020**, 12, 622360	5.3	1
118	Sex differences in CSF biomarkers of Alzheimer disease. **2021**, 107-123		
117	Cell Cycle and Chromosome Segregation Defects in Alzheimer Disease. **2005**, 55-78		2
116	Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A42-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD). **2007**, 167-193		1
115	Inflammatory Processes Exacerbate Degenerative Neurological Disorders. **2009**, 117-124		2
114	Microglial Activation, Cytokine Production, and Local Inflammation in Focal Brain Ischemia. **2003**, 115-145		1
113	Molecular Pathology of Alzheimer Disease and Related Disorders. **1999**, 603-654		18
112	Neuroinflammation and Alzheimer Disease. **1997**, 15-19		1
111	Molecular Pathobiology of Alzheimer Disease. **1994**, 209-238		1
110	Glial Activation as a Common Denominator in Neurodegenerative Disease: A Hypothesis in Neuropathophysiology. **1993**, 359-381		2
109	Inflammatory Mediators in Alzheimer Disease. **1997**, 177-198		8
108	Inflammatory Mechanisms of Alzheimer Disease. **1998**, 177-193		6
107	Distinct Roles of Cyclooxygenase-1 and Cyclooxygenase-2 in Inflammatory and Excitotoxic Brain Injury. **2011**, 119-136		1
106	The Involvement of A in the Neuroinflammatory Response. **2007**, 52-82		1
105	Complement, neuroinflammation and neuronal degeneration in Alzheimer disease. **2001**, 15-20		1

104	Immunological Markers and Neuropathological Lesions in Alzheimer's Disease. **1988**, 7-16	7
103	Neurodegenerative Alzheimer-like Pathology in PDAPP 717V -iF Transgenic Mice. **1997**, 105-119	5
102	Cytokines in Alzheimer's and Other Neurodegenerative Diseases. **1996**, 127-146	1
101	Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics. **2000**, 387-414	17
100	Alzheimer disease and neuroinflammation. **2000**, 59, 53-7	81
99	Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. **1990**, 29, 195-206	15
98	Single nucleus sequencing fails to detect microglial activation in human tissue.	8
97	Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's disease.	1
96	Effector function of anti-pyroglutamate-3 A antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. **2020**, 12, 12	15
95	Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751)(SL) mice. **2011**, 6, e20153	40
94	Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid- peptide injection in rats. **2013**, 8, e53117	80
93	Ferulic acid is a nutraceutical secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. **2013**, 8, e55774	118
92	CCAAT-enhancer binding protein- expression and elevation in Alzheimer's disease and microglial cell cultures. **2014**, 9, e86617	30
91	Characterization of Novel Src Family Kinase Inhibitors to Attenuate Microgliosis. **2015**, 10, e0132604	10
90	Effects of N-3 Polyunsaturated Fatty Acids on Dementia. **2017**, 9, 1-9	30
89	Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. **2009**, 1, 234-44	70
88	Persistent infections, immune-senescence and Alzheimer's disease. **2016**, 3, 135-42	16
87	Microglia in Alzheimer's Disease. **2020**, 17, 29-43	7

86	A Protective Role of Translocator Protein in Alzheimer's Disease Brain. **2020**, 17, 3-15	3
85	Periodontal Pathogens and Neuropsychiatric Health. **2020**, 20, 1353-1397	7
84	Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy. **2018**, 16, 508-518	157
83	Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. **2010**, 9, 168-73	78
82	Innate immunity in Alzheimer's disease: a complex affair. **2013**, 12, 593-607	63
81	Microglia Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF- levels. **2020**, 9,	14
80	Microglia. **2001**, 209-224	
79	Role and regulation of early complement activation products in Alzheimer disease. **2001**, 67-87	
78	Cellular Reactions in Response to Acute Focal Brain Ischemia. **2003**, 21-29	
77	Cytokines and Neurodegeneration. **2005**, 163-191	
76	Endocannabinoids in Alzheimer's Disease. **2008**, 395-405	
75	Validation of Animal Models of Dementia: Neurochemical Aspects. **2011**, 169-185	
74	Neuroprotection Versus Neurotoxicity. **2014**, 145-172	0
73	Role of Complements and Immunoglobulins in Alzheimer Disease. **2014**, 04, 285-298	
72	Implications of immunomodulant therapy in Alzheimer's disease. **1988**, 32, 21-42	5
71	Epitopes Characteristic of Paired Helical Filaments Demonstrated in Microglial Cells and Macrophages of the Meninges: A Possible Laboratory Diagnosis of Alzheimer Disease from Cerebrospinal Fluid?. **1989**, 66-72	
70	Host Immune Responses to Neural Transplantation: A Possible Model for Autoimmune Diseases of the Central Nervous System. **1989**, 63-72	
69	Characteristics of Reactive Microglia in Alzheimer and Parkinson Disease Brain Tissue. **1990**, 381-384	

68	Immune System Reaction to Model Lesions of Rat Brain. **1990**, 407-410	
67	Antithyroid Antibodies: Behavioral Significance. **1990**, 362-370	
66	Herpes Simplex Virus Type 1 Transcription during Latent Infections of Mouse and Man. **1991**, 277-286	1
65	Central Nervous System: Viral Infection and Immune-Mediated Inflammation. **1994**, 321-347	
64	Inflammation in the CNS and in Alzheimer Disease. **1996**, 147-168	
63	Pathological Changes in the Elderly Human Brain. **1997**, 5-114	
62	Microgliosis and Impaired Cognition. **1998**, 109-125	
61	Trophic Factors and Cell Adhesion Molecules Can Drive Dysfunctional Plasticity and Senile Plaque Formation in Alzheimer's Disease through a Breakdown in Spatial and Temporal Regulation. **1999**, 529-XVI	
60	Literaturverzeichnis. **2008**, 113-147	
59	Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration.	1
58	Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers. **2020**, 11, 3315-3349	0
57	Immunophenotypic features of epiplexus cells and their response to interferon gamma injected intraperitoneally in postnatal rats. **1994**, 185 (Pt 1), 75-84	5
56	Upregulation and induction of surface antigens with special reference to MHC class II expression in microglia in postnatal rat brain following intravenous or intraperitoneal injections of lipopolysaccharide. **1994**, 184 (Pt 2), 285-96	11
55	Expression of major histocompatibility complex and leukocyte common antigens in amoeboid microglia in postnatal rats. **1991**, 177, 117-26	52
54	Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. **1990**, 136, 1101-14	153
53	A comparative immunohistochemical study of Kuru and senile plaques with a special reference to glial reactions at various stages of amyloid plaque formation. **1991**, 139, 589-98	56
52	Accumulation of amyloid precursor protein in neurons after intraventricular injection of colchicine. **1992**, 140, 787-94	43
51	Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. **1994**, 145, 771-5	41

50	Ccr2-64i and Ccr5 Δ32 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 Δ32 Polymorphisms in Alzheimer's disease). **2012**, 15, 937-44		13
49	At the intersection of sulfur redox chemistry, cellular signal transduction and proteostasis: A useful perspective from which to understand and treat neurodegeneration. **2021**, 178, 161-173		1
48	A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.. *Ageing Research Reviews*, **2021**, 74, 101542	12	1
47	Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.. **2022**, 2022, 9484217		4
46	Spatial transcriptomic analysis reveals inflammatory foci defined by senescent cells in the white matter, hippocampi and cortical grey matter in the aged mouse brain.. **2022**, 1		1
45	Probable Reasons for Neuron Copper Deficiency in the Brain of Patients with Alzheimer's Disease: The Complex Role of Amyloid. **2022**, 10, 6		0
44	Protective Role of Microglia on Neuronal Survival after Exposure to Amyloid Beta.. **2022**, 58, 13-17		
43	Alzheimer's Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy - Bridging the Missing Link.. *Frontiers in Cellular Neuroscience*, **2021**, 15, 811852	6.1	1
42	Microglia in Alzheimer's Disease: An Unprecedented Opportunity as Prospective Drug Target.. *Molecular Neurobiology*, **2022**,	6.2	3
41	Droplet Degeneration of Hippocampal and Cortical Neurons Signifies the Beginning of Neuritic Plaque Formation.. *Journal of Alzheimer's Disease*, **2021**,	4.3	2
40	Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients.. *Frontiers in Aging Neuroscience*, **2021**, 13, 762649	5.3	1
39	The Role of Immunity in Alzheimer's Disease.. **2022**, e2101166		1
38	Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in App mice.. **2022**, 5, 245		3
37	Contribution of "Genuine Microglia" to Alzheimer's Disease Pathology.. *Frontiers in Aging Neuroscience*, **2022**, 14, 815307	5.3	
36	Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease.. *Cell Metabolism*, **2022**,	24.6	7
35	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.. *Frontiers in Aging Neuroscience*, **2022**, 14, 858429	5.3	0
34	Glial Cells in Alzheimer's Disease: From Neuropathological Changes to Therapeutic Implications.. *Ageing Research Reviews*, **2022**, 101622	12	4
33	Data_Sheet_1.PDF. **2019**,		

32	Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease.. *Journal of Alzheimer's Disease*, **2022**,	4.3	
31	The aging immune system in Alzheimer's and Parkinson's diseases.. *Seminars in Immunopathology*, **2022**, 1	12	1
30	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. *Journal of Neuropathology and Experimental Neurology*, **2022**, 81, 387-413	3.1	0
29	Neuroimmune contributions to Alzheimer disease: a focus on human data. *Molecular Psychiatry*,	15.1	0
28	p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia. *Molecular Neurobiology*,	6.2	1
27	Microglial Priming in Infections and Its Risk to Neurodegenerative Diseases. *Frontiers in Cellular Neuroscience*, 16,	6.1	0
26	Microglia and border-associated macrophages in the central nervous system. **2022**, 181-212		
25	A Dichotomous Role for FABP7 in Sleep and Alzheimer Disease Pathogenesis: A Hypothesis. *Frontiers in Neuroscience*, 16,	5.1	
24	Crossing borders in Alzheimer disease: A T cell perspective. *Advanced Drug Delivery Reviews*, **2022**, 188, 114398	18.5	1
23	The relationship between TLR4/NF-B/IL-1 signaling, cognitive impairment, and white-matter integrity in patients with stable chronic schizophrenia. 13,		
22	How the immune system shapes neurodegenerative diseases. **2022**, 45, 733-748		0
21	Sex-specific effects of ethanol consumption in older Fischer 344 rats on microglial dynamics and A(1-42) accumulation. **2022**,		0
20	The relationships between neuroglial alterations and neuronal changes in Alzheimer disease, and the related controversies I: Gliopathogenesis and glioprotection. **2022**, 14, 117957352211287		0
19	Alzheimer's Disease. **2003**, 228-259		0
18	Anti-inflammatory effects of 9-cis-retinoic acid on amyloid treated human microglial cells. **2022**, 20, 1721727X2211436		1
17	Neuroimmune mechanisms underlying Alzheimer disease: Insights into central and peripheral immune cell crosstalk. **2023**, 84, 101831		0
16	Identification of pyrocatechol, a coffee ingredient that exerts antineuroinflammatory effects by inhibiting NF-kappaB.		0
15	Neuroinflammation, immune response and synuclein pathology: how animal models are helping us to connect dots.		0

14	Microglial Activation and Priming in Alzheimer Disease: State of the Art and Future Perspectives. **2023**, 24, 884	1
13	The Mechanism of Two Benzaldehydes from Aspergillus terreus C23-3 Improve Neuroinflammatory and Neuronal Damage to Delay the Progression of Alzheimer Disease. **2023**, 24, 905	0
12	The association of astrogliosis and microglial activation with aging and Alzheimer's disease pathology in the chimpanzee brain.	0
11	LilrB3 is a putative cell surface receptor of APOE4.	0
10	The Vascular-Immune Hypothesis of Alzheimer Disease. **2023**, 11, 408	1
9	Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications. **2023**, 13, 329	1
8	Molecular Imaging of Neuroinflammation in Alzheimer Disease and Mild Cognitive Impairment. **2023**, 301-326	0
7	Neuron-Microglia Crosstalk in Neuropsychiatric Disorders. **2023**, 3-15	0
6	Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway. **2023**, 161, 114473	0
5	Retinal pathological features and proteome signatures of Alzheimer disease. **2023**, 145, 409-438	1
4	Cornuside, by regulating the AGEs-RAGE-IB ERK1 /2 signaling pathway, ameliorates cognitive impairment associated with brain aging.	0
3	Using Optogenetics to Model Cellular Effects of Alzheimer Disease. **2023**, 24, 4300	0
2	Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases. **2023**, 24, 5925	0
1	The Multifaceted Role of WNT Signaling in Alzheimer Disease Onset and Age-Related Progression. **2023**, 12, 1204	0